858 Therapeutics

About 858 Therapeutics

858 Therapeutics is a clinical-stage drug discovery and biotechnology company focused on developing small molecule drugs targeting novel therapeutic areas in oncology and immunology. The company is dedicated to discovering innovative drugs for patients with cancer and immune diseases, and is headquartered in San Diego, CA.

Products & Services

Small Molecule Drugs:A portfolio of drugs targeting novel therapeutic areas in oncology and immunology.

PARG Inhibitor:Lead program in early clinical development.

Specialties

Synthetic Lethality Innate Immunity RNA Modulation Oncology Immunology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2024-09-26 FD: 2024-09-26	7 investors

Series B Latest

2024-09-26

$50.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Timothy Yap

Medical Oncologist and Physician-Scientist

S

Stephen Taylor

Leech Professor of Pharmacology and Head of Division for Cancer Sciences

R

Ravi Majeti

RZ Cao Professor of Medicine (Hematology) and Director of the Institute for Stem Cell Biology and Regenerative Medicine

S

Samie Jaffrey

Greenberg-Starr Professor in the Department of Pharmacology at the Weill Cornell Medical College

M

Michael G. Kharas

Associate Investigator

S

Schraga Schwartz

Principal Investigator and Robert Edward and Roselyn Rich Manson Career Development Chair in the Department of Molecular Genetics

View 22 more team members with Pro

Unlock Full Team Directory

Recent News